期刊文献+

临床分离白念珠菌 ERG4基因高表达与唑类抗真菌药物耐药的关系

Relationship between ERG4 gene overexpression and azole resistance in clinical Candida albicans strains
原文传递
导出
摘要 目的:探讨临床分离白念珠菌 ERG4基因高表达与唑类抗真菌药物耐药的关系。方法 M27-A2微量肉汤稀释法对34株临床分离白念珠菌菌株进行体外药物敏感性试验。抽提白念珠菌 ERG4基因的总RNA,并逆转录合成 cDNA,采用实时荧光定量 PCR(FQ-RT-PCR)方法检测 ERG4基因 mRNA 表达水平。结果白念珠菌耐氟康唑菌株组 ERG4基因表达量(4.20±2.56)高于敏感组(1.72±1.33)(t =3.99,P 〈0.05);耐伊曲康唑组(3.60±2.47)高于敏感组(1.66±1.61)(t =3.71,P 〈0.05);耐伏立康唑组(3.99±2.72)高于敏感组(2.07±1.58)(t =2.91,P 〈0.05);对氟康唑、伊曲康唑、伏立康唑同时耐药菌株组(4.49±2.73)显著高于敏感组(1.69±1.82)(t =3.81,P 〈0.05)。结论临床分离白念珠菌耐药菌株 ERG4基因高表达与氟康唑、伊曲康唑和伏立康唑耐药及交叉耐药有关,但白念珠菌 ERG4基因高表达在耐药中的作用还有待于通过基因下调进一步研究证实。 Objective To explore the relationship between ERG4 gene overexpression and azole resistance in clinical Candida albicans strains. Methods The National Committee for Clinical Laboratory Standards (NCCLS)M27-A2 broth microdilution method was conducted to evaluate antifungal susceptibility of 34 clinical Candida albicans isolates in vitro. Total RNA was extracted from these Candida albicans strains and transcribed into cDNA. Real-time fluorescence-based quantitative PCR was performed to determine the mRNA expression of ERG4 gene. Statistical analysis was carried out by a two-sample t-test. Results The expression level of ERG4 mRNA was significantly higher in fluconazole-resistant than in -sensitive Candida albicans strains (4.20 ± 2.56 vs. 1.72 ± 1.33, t = 3.99, P 〈 0.05), higher in itraconazole-resistant than in -sensitive Candida albicans strains (3.60 ± 2.47 vs. 1.66 ± 1.61, t = 3.71, P 〈 0.05), and higher in voriconazole-resistant than in -sensitive Candida albicans strains (3.99 ± 2.72 vs. 2.07 ± 1.58, t = 2.91, P 〈0.05). Further more, increased ERG4 mRNA expression was also observed in isolates cross-resistant to all the three azole antifungal agents compared with those susceptible to all of them (4.49 ± 2.73 vs. 1.69 ± 1.82, t = 3.81, P 〈 0.05). Conclusions The overexpression of ERG4 gene may be associated with cross resistance to fluconazole, itraconazole and voriconazole in clinical Candida albicans strains, but its exact role is expected to be investigated through downregulation of the ERG4 gene.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2015年第8期531-534,共4页 Chinese Journal of Dermatology
基金 山西省基础研究项目(2012011045-3) 山西省青年科技研究基金(2012021035-3) 山西省卫生和计划生育委员会科研课题计划(2014044) 山西医科大学科技创新基金(01201013)
关键词 白色念珠菌 基因 抗药性 真菌 抗真菌药 基因表达 ERG4 ERG4 Candida albicans Genes Drug resistance,fungal Antifungal agents Gene expression
  • 相关文献

参考文献12

  • 1Yapar N. Epidemiology and risk factors for invasive candidiasis [J]. Ther Clin Risk Manag, 2014, 10: 95-105.
  • 2张伟,林兆奋,赵瑾,许诗琼,单红卫.重症监护病房真菌谱及耐药性6年变化趋势[J].中国真菌学杂志,2014,9(1):24-27. 被引量:5
  • 3Basma R, Barada G, Ojaimi N, et al. Susceptibility of Candida a/bicans to common and novel antifungal drugs, and relationship between the mating type locus and resistance, in Lebanese hospital isolates[J]. Mycoses, 2009, 52(2): 141-148.
  • 4Espinel-Ingroff A, Pfaller MA, Bustamante B, et al. Multilaboratory study of epidemiologieal cutoff values for detection of resistance in eight Candida species to flueonazole, posaconazole, and voriconazole [J]. Antimicrob Agents Chemother, 2014, 58 (4): 2006-2012.
  • 5Vale-Silva LA, Coste AT, Ischer F, et al. Azole resistance by loss of function of the sterol AS'6-desaturase gene (ERG3) in Candida albicans does not necessarilv decrease virulence [J]. AntimicrobAgents Chemother, 2012, 56 (4): 1960-1968.
  • 6Lai MH, Bard M, Pierson CA, et al. The identification of a gene family in the Saeeharomyces cerevisiae ergosterol biosynthesis pathway[ J ]. Gene, 1994, 140( 1 ): 41-49.
  • 7Zweytick D, Hrastnik C, Kohlwein SD, et al. Biochemical charac- terization and subcellular localization of the sterol C-24 (28) reductase, erg4p, from the yeast saeeharomyees eerevisiae[ J ]. FEBS Lett, 2000, 470( 1 ): 83-87.
  • 8He X, Zhang B, Tan H. Overexpression of a sterol C-24(28 ) reduetase increases ergosterol production in Saeehazgmyces eerevisiae[J]. Biotechnol Lett, 2003, 25( 10): 773-778.
  • 9He X, Guo X, Liu N, et al. Ergosterol production from molasses by genetically modified Saccharomyces cerevisiae [J]. Appl MierobiolBiotechnol, 2007, 75( 1 ): 55-60.
  • 10Henry KW, Cruz MC, Katiyar SK, et al. Antagonism of azole activity against Candida albicans following induction of muhidrug resistance genes by selected antimicrobial agents [J]. Antimicrob Agents Chemother, 1999, 43(8): 1968-1974.

二级参考文献22

  • 1Bassetti M, Ansaldi F, Nicolini L, et al. Incidence of candidae- mia and relationship with fluconazole use in an intensive care u- nit [ J ]. J Antimicrob Chemother, 2009, 64 ( 3 ) :625-629.
  • 2Hope W, Morton A, Elsen DP. Increase in prevalence of nosoco- mial non- Candida albicans candidaemia and the association of Candida krusei with fluconazole use[J]. J Hosp Infect, 2002,5 (10) :56.65.
  • 3Rubio PM, Sevilla J, Gonztalez-Vicent M, et al. Increasing inci- dence of invsiveaspergillosis in pediatric hematology oncology pa- tients over the last decade: a retrospective single centre study [J]. J Pediatr Hematol Oncol, 2009, 31(9) :642-646.
  • 4Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the AR- TEMIS DISK Global Antifungal Surveillance study, 1997 to 2005 : an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole deter- mined by CLSI standardized disk diffusion testing[ J ]. J Clin Mi- crobio1,2007, 45 (6) : 1735-1745.
  • 5Bowyer P, Moore CB, Rautemaa R,et al. Azole antifungal resist- ance today: focus on Aspergillus [ J ]. Curr Infect Dis Rep ,2011 ; 13(6) :485-491.
  • 6Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with heahhcare-asso-ciated infections : annual summary of data reported to the Nation- al Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 [ J ]. Infect Control Hosp Epidemiol, 2008,29 ( 11 ) :996-1011.
  • 7Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata :an emerging oral opportunistic pathogen [ J ]. J Dent Res, 2007,86 (3) : 204-215.
  • 8Eggimann P, Garbina J, Pittet D. Epidemiology of Candida spe- cies infections in critically ill non-immunosuppressed patients. Infections in critically ill non-immunosuppressed patients [ J ]. Lancet Infect Dis,2008,3 (2) :685-702.
  • 9Arendrup MC, Fisher BT, Zaoutis TE. Invasive fungal infections in the paediatric and neonatal population: diagnostics and man- agement issues [ J ]. Clin Mierobiol Infect, 2009, 15 ( 7 ) : 613- 624.
  • 10Comely A, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non- neutropenic adult patients [ J]. Clin Microbiol Infect, 2012,18 (Suppl 7) :19-37.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部